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Abstract 12 
A strategic approach to control the polymorphism of two related drugs by introducing a drug-13 
mimetic imide functional group into the molecular weight organogelator structure is presented. 14 
This was achieved with novel aminoglutethimide-derived bis(urea) organogelators designed to 15 
form gels that act as targeted crystallization media for (±)-thalidomide and barbital. The 16 
organogelators prevent concomitant crystallization, a serious issue for drug formulation and 17 
development. This work demonstrates the potential to control concomitant crystallization with 18 
rationally designed supramolecular gelators.  19 
Introduction 20 
 2 
Supramolecular gels are formed through the self-assembly of gelators (typically at low 21 
concentrations i.e. <2% by mass) into filaments which entangle and branch to form a three-22 
dimensional network that immobilizes the solvent to produce a viscoelastic material.1–5 These 23 
gelators can be relatively straightforward to synthesize and functionalize, with potential 24 
applications in catalysis, biomedical research, drug delivery and pharmaceutical crystallization.6–25 
11 Bis(urea) gelators, in particular, can be synthetically modified to design gelators with desired 26 
functionalities and specific properties while retaining their gel-forming ability.12 Generally, 27 
bis(urea) gels are thermally reversible as they are formed through reversible non-covalent 28 
interactions and their gelation behavior can be manipulated by altering the experimental 29 
conditions.2,13–15  Furthermore, the prevention of convection effects, reduced solvent evaporation 30 
rate and the possibility of designing drug-specific binding functionality, means that 31 
supramolecular gels are emerging as effective media for pharmaceutical crystallization.11,16,17 32 
Drug solid form screening, solid form control and crystal morphology are of key industrial 33 
significance.18,19 Crystal form control has vital importance in the pharmaceutical development 34 
process as different crystal structures (polymorphs) or solvated forms (solvates) of the same drug 35 
exhibit different physiochemical properties such as solubility, tabletability, melting behavior, 36 
hydration stability, bulk density and bioavailability, which eventually impact on the overall drug 37 
efficacy.18 In addition, factors like crystal morphology and particle size also need careful attention 38 
as they can influence the drug physiochemical, formulation and processing properties.20 Moreover, 39 
a thorough understanding of the solid forms landscape can represent intellectual property 40 
opportunities.21 Nucleation events and crystal growth can be guided at interfaces by molecular 41 
recognition. Crystallization using heterogeneous surfaces such as a self-assembled monolayer 42 
(SAM),19 or a polymer additive and techniques like laser-induced crystallization,22 are also being 43 
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incorporated into pharmaceutical screening and solid form control and discovery methods.23 New 44 
crystallization methods such as nanoconfinement, nanodroplet crystallization,24 the use of tailored 45 
additives25,26 and careful temperature control27 are significantly expanding solid form landscapes. 46 
Bora et al. recently reported that crystallization on functionalized SAM surface could effectively 47 
control concomitant nucleation of flexible molecules.19  48 
Recent work has demonstrated the feasibility of gel-phase crystallization to control crystal size, 49 
morphology and polymorphic outcome.11,16,28,29 It has been proposed that the gel fibers can act as 50 
a surface for templated nucleation of active pharmaceutical ingredients (APIs). Different solid-51 
state crystal forms (polymorphs) can differ in lattice energy by only a few kJ mol-1 30,31 and so the 52 
presence of the gel fiber surface can bias the system towards the crystallization of a particular 53 
form.32 Depending on the gel-solute interactions, gels offer the possibility of obtaining new forms 54 
or metastable solid forms that are not be obtainable from the conventional crystallization 55 
methods.11,17 Functionalized gels can offer potential alternate nucleation sites and hence can 56 
influence the crystallization outcome. Polymorphic control of the highly polymorphic molecule 57 
ROY has been demonstrated by utilizing a rationally designed organogel as the crystallization 58 
medium.16 Other modifications of crystal properties such as size, morphology, and change in 59 
polymorphism in gel phase crystallization have been reported.11,16,17,29,33  60 
While often the discovery of gelators is serendipitous, bis(urea)s are prone to form gels in the 61 
presence of a wide variety of terminal substituents as they often aggregate via one-dimensional 62 
hydrogen bonding to form highly anisotropic morphologies that are commonly linked to 63 
gelation.4,12 As the urea groups are expected to be involved in urea -tape like hydrogen bonding 64 
it is possible to append drug-mimetic functional groups at the periphery of the gelator that are 65 
available to interact with the API solute and hence influence its crystallization. 66 
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Despite its notorious history, (±)-thalidomide (THL) has attracted considerable clinical interest 67 
in recent years due to its unique pharmacological effect against several diseases, especially 68 
cancer.34 Racemic THL has two known solid forms, termed  and .35 Barbital (BAR) was the 69 
first commercially available barbiturate and is a well-known sedative.36 It is highly polymorphic 70 
with six known non-solvated forms.36 Crystal structures of three polymorphs of BAR i.e. forms I, 71 
III and V have been reported, which exhibit packing polymorphism, and are known to crystallize 72 
concomitantly (Scheme 1).36,37 Concomitant polymorphism involves the crystallization of 73 
different forms, from the same crystallization batch and it is common when the crystal packing 74 
energy differences between forms are relatively insignificant.19,38,39 However, formulation of a 75 
pure single form of a drug is crucial in the pharmaceutical industry since varying amounts of 76 
different polymorphs can give rise to an inconsistent product profile and performance. Therefore 77 
attaining control over concomitant polymorphism as observed for BAR is essential from its 78 
efficacy and formulation point of view.40  79 
In this work, we have designed three new bis(urea)-based low molecular weight gelator 80 
(LMWG) bearing the drug-mimetic imide group that occurs in important drug classes such as 81 
barbiturates and thalidomide and its analogs to act as a potential site of interaction with the target 82 
APIs (Scheme 2). We show that these targeted gelators achieve control over the concomitant 83 
polymorphism of BAR and influence the outcome of THL crystallizations.  84 
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 85 
Scheme 1 Chemical structures of APIs (a) barbital (BAR) and (b) (±)-thalidomide (THL); 86 
concomitant polymorphism from solution crystallization of (c) BAR from cyclohexanone and (d) 87 
THL from nitromethane. Needle β form (red circle) and plate-shaped α form (blue circle) of THL. 88 
 89 
 90 
Scheme 2 Design of drug mimetic gelators G1–3, with the imide group shown in blue. 91 
 92 
Results and Discussion 93 
Synthesis  94 
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The three gelators (G1 – G3) were synthesized in good yield using the commercially available 95 
(±)-aminoglutethimide as the precursor and the appropriate diisocyanate (see Electronic 96 
Supporting Information, Schemes S1 – S3). The gelators were characterized by nuclear magnetic 97 
resonance (NMR) spectroscopy, Fourier-transform infrared (FTIR) spectroscopy, mass 98 
spectrometry and elemental analysis (see ESI). 99 
 100 
Gel screening and Characterization 101 
Gel screening of G1, G2 G3 was carried out using a wide range of solvents and solvent 102 
combinations at 2 % (w/v) (Table 1). Samples were dissolved with gentle heating and sonication 103 
until full dissolution. Gel formation was typically observed upon cooling to room temperature 104 
within a few minutes though in some cases gelation took several hours. Gel formation was assessed 105 
qualitatively by simple inversion of the sample vial. Gelator G1 forms gels in 13 of the 29 solvents 106 
and solvent combinations tested including some alcohols, cyclic ketones, 1,4-dioxane and nitro 107 
compounds (See ESI Figure S4).  108 
The low solubility of gelator G1 prevents the formation of gels in most alcoholic solvents 109 
such as methanol and 1-propanol. The addition of a few drops of DMSO readily dissolved the 110 
gelator with further heating so that it forms gels in all the alcoholic solvents tested upon cooling. 111 
The critical gelation concentration (CGC) for G1 is typically 1.7 – 2 % (w/v) for alcoholic solvents, 112 
while in the case of nitrobenzene, cyclohexanone, cyclopentanone, 1,4-dioxane, tetrahydrofuran a 113 
lower CGC of 0.8 – 1 % (w/v)  was observed. While G1 is an effective gelator, G2 and G3 form 114 
gels in only in two or three different solvents or solvent mixtures (Table 1). Gelator G2 forms gels 115 
in nitrobenzene and a 3:1 mixture of ethanol and cyclohexane (see ESI Figure S4b) with CGC of 116 
0.8 and 0.9 % (w/v), respectively. G3 gels nitrobenzene, nitromethane and a 2:1 toluene/ethyl 117 
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acetate mixture (see ESI Figure S4c) with a CGC of 0.8 % (w/v) in each case. All gels were either 118 
translucent or opaque and became more opaque over time. This is commonly attributed to fibers 119 
laterally associating to form larger bundles, which scatter light more, thus appearing more 120 
opaque.41,42 FT-IR analysis of the gels demonstrated a lowering of  the IR frequency for 121 
carboxamide peak (~1692 cm-1) for the gels, which we attribute to intermolecular hydrogen 122 
bonding between the gelator molecules (ESI Figure S5). 123 
 124 
Table 1 Gel screening results for G1, G2 and G3, all at 2% (w/v).  125 
Solvent G1  G2 G3 
1,2,4-trichlorobenzene P S S 
2-propanol PG PG S 
Acetone P S S 
Ethanol G PG PG 
Methanol PG PG PG 
Methanol+ DMSO G PG PG 
1-Pentanol G PG PG 
1,4-Butanediol G PG PG 
1-Propanol PG PG PG 
1-Propanol+ DMSO  G PG PG 
1-Butanol G S PG 
2-Butanol PG IS PG 
2-Butanol+ DMSO  G S PG 
Benzyl Alcohol PG S S 
Chloroform IS IS IS 
Dimethyl sulfoxide S S S 
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Dimethylformamide S S S 
Ethyl Acetate IS IS S 
Nitrobenzene G G G 
Nitromethane G* PG G 
1,4-Dioxane G S S 
Tetrahydrofuran G S S 
Cyclohexanone G S P 
Cyclopentanone G P P 
Toluene P P S 
H2O P S S 
EtOH: Cyclohexane (3:1) PG G PG 
Toluene: Ethyl acetate (2:1) PG PG G 
P= Precipitate, G= Gel, PG= Partial Gel, I= Insoluble with heating. * Very soft gel 126 
 127 
 The sol phase transition temperature, Tgel, was recorded by heating the gels and recording 128 
the temperature at which a small ball bearing fell through the sample, indicating disruption of the 129 
gel network.43 Gels formed with G1 were found to be generally quite stable with a Tgel of 97 °C at 130 
a concentration of 2% (w/v) for cyclohexanone (see ESI, Table S1). The gel of G3 in nitromethane 131 
has a much lower Tgel of 45
 °C at 2 % (w/v). In nitrobenzene and a mixture of toluene/ethyl acetate 132 
(2:1) the Tgel values for G3 are 101 and 83 °C, respectively. The latter value is above the 77 °C
 133 
boiling point of ethyl acetate and was evaluated in a sealed container. This relatively high Tgel 134 
suggests that gels of G3 may be relatively robust. 135 
Representative gels were characterized using oscillatory rheology. In all cases, the storage 136 
modulus (G′) was at least an order of magnitude greater than the loss modulus (G′′), indicative of 137 
the solid-like nature of the materials (Figure 1).44,45 The mechanical properties of the gels were 138 
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relatively insensitive to the oscillation frequency, with G′ higher than G″ in all cases, and they 139 
remain almost constant over the entire angular frequency range (ESI Figure S7), again typical 140 
behavior for supramolecular gels. Scanning electron microscopy (SEM) was used to image the 141 
morphology of the xerogels formed from G1, G2 and G3 a highly entangled network as observed 142 
for all samples (Figure 1b). The SEM sample of G1 is obtained from drying a 2% (w/v %) gel in 143 
ethanol and shows a helical twisted morphology (Figure 1bi). A cylindrical ribbon type 144 
morphology is observed for a 1 % (w/v %) xerogel of G2 obtained from nitrobenzene (Figure 145 
1bii). A dense network of helical morphology is observed for 1 % (w/v %) xerogel of G3 in 146 
nitromethane (Figure 1biii).  147 
 148 
Figure 1 (a) Oscillatory stress sweeps at a constant frequency (1 Hz) (i) G1, (ii) G2 and (iii) G3. 149 
(i) Cyclohexane (blue), nitrobenzene (green), butanol (orange); (ii) ethanol: cyclohexane 1% (w/v) 150 
(black), 2 % (w/v) (purple); (iii) nitromethane (red), toluene: ethyl acetate (2:1) (green). In all cases 151 
■ refer to G′ (elastic moduli) and ● refer to G′′ (viscous moduli). (b) SEM images of the xerogels 152 
(i) G1, (ii) G2 and (iii) G3 demonstrates the fibrous nature of the gels. (Scale bar: 2 µm) 153 
 154 
 155 
Crystallization of Barbital 156 
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The UNI force-field introduced by Gavezzotti and Filippini46,47 and implemented in the 157 
Cambridge Crystallographic Data Centre Mercury package (Mercury 4.2.0)48 was used to calculate 158 
the relative packing energy of the BAR polymorphic forms based on the single-crystal structures 159 
(DETBA01-12) deposited in the Cambridge Structural Database.49 The packing energies are 160 
comparable with packing energy –114.9, –118.2 and –119.5 kJ mol–1 for polymorphs I, III and V, 161 
respectively. These similar packing energies are consistent with the observation of concomitant 162 
polymorphism. 163 
 164 
Table 2 Comparison of crystallization outcome from solution and gel crystallization of barbital.  165 
Solvent Solvent 
Crystallization 
G1 G2 G3 
Ethanol I, III, IV, V III (prism), V No gel No gel 
1-Butanol I, III, V III (rod) No gel No gel 
1,4-Butane-diol I, III, V III (prism) No gel No gel 
1-Pentanol I, III, IV, V III (prism) No gel No gel 
Nitrobenzene III III III III 
Nitromethane III (needle)  III (prism) No gel Gel Unstable 
Cyclohexanone I, III, IV, V III (prism) No gel No gel 
Toluene/ethyl 
acetate (2:1) 
III and V No gel III (prism) No gel 
EtOH/cyclohexane 
(3:1) 
III and V No gel No gel III (prism) 
Solution crystallizations were performed by slow evaporation in a sealed vial with pinhole 
openings at room temperature. Crystallizations of barbital in the gels were carried out in 
parallel to solution crystallization, at 10% w/v. 
 166 
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The tendency of BAR to crystallize multiple forms concomitantly is well known and occurs in 167 
many solvents (Table 2).36,37 Similarly subliming BAR between 100 and 120°C results in the 168 
concomitant crystallization of forms I, IV, V and III.36 MacDonald et al. employed chemically 169 
modified surfaces in microfluidic channels to control the nucleation of barbital polymorphs, 170 
however, they were not able to control selectivity between forms I, III and IV at the surface of 171 
SAMs.37 Gel phase crystallizations of BAR were carried out in parallel to solution crystallization, 172 
typically at 10% w/v and crystals typically formed in 3-4 days (see Experimental for details). The 173 
crystals that were obtained from control solution crystallization from alcoholic solvents gave rise 174 
to concomitant crystallization of polymorphs I, III, IV and V of BAR which were identified by 175 
optical microscopy, single-crystal unit cell determination for at least five crystals, PXRD, DSC 176 
and FT-IR analysis.36 Form I and III proved to be more abundant by solvent crystallization and 177 
occurred along with forms V and IV. However, form IV transform to Form I within 30 minutes 178 
outside solvent at room temperature and demonstrated by FT-IR analysis (ESI, Figure S8). Under 179 
the same experimental condition i.e. 100 mg/mL of barbital, gels of G1 in 1-butanol (1.8 w/v %), 180 
1-pentanol (1.8 w/v %), and 1,4-butanediol  (1.8 w/v %), produced only the kinetic form III of 181 
BAR. However, in the case of ethanol (1.7 w/v %) trace amount of crystals of another kinetic form, 182 
form V was also observed along with polymorph III. In the case of nitrobenzene, no differences 183 
between crystals obtained from the solution and gel phase crystallization were observed. This is 184 
not surprising since the kinetic form is already favored in nitrobenzene. The solution crystallization 185 
of BAR from nitromethane (10 w/v %) resulted in dense needle-shaped crystals (Figure 3aiii). 186 
These crystals were analyzed by FTIR spectroscopy and unit cell determination and were found to 187 
be a concomitant mixture of polymorphs III and V. However, nitromethane gels of G1 (2 w/v %) 188 
produced large prism-shaped crystals of polymorph III without the concomitant presence of Form 189 
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V. Thus, in contrast to solution crystallization methods, gel phase crystallization of BAR using the 190 
gelator G1 exhibits high selectivity for the kinetic form III polymorph. This selectivity is also 191 
observed for gels formed using G2 and G3 in two different solvents implying that the common 192 
imide on all the gelators plays major role in control the crystallization outcome. It is possible that 193 
the interaction of the drug molecules with the gel fiber surface might increase the nucleation rate 194 
of the kinetic form and thereby suppresses the nucleation of competing forms. A comparison 195 
between gel phase and solution phase crystallization outcomes is shown in Figure 3. In the 196 
presence of gelator in the gel state can alter the crystallization behavior of barbital and thereby 197 
prevent the concomitant crystallization and confirmed the observations from PXRD, DSC, FT-IR 198 
and SCXRD. These observations were further verified by conducting additional gel phase 199 
crystallizations using previously reported gelators that do not contain the imide functionality; G4 200 
contains nitro aryl groups,16 and G5 a salt gelator bearing carboxylate groups (Figure 2).50 All 201 
crystallizations in these gels failed to prevent concomitant polymorphism. This indicates that it the 202 
imide functionality of the mimic gelators rather than the growth in a viscous gel network that 203 
prevents concomitant crystallization either enhancing nucleation of Form III or, more likely, 204 
suppressing nucleation of the other forms. Furthermore, quantitative analysis of the intermolecular 205 
interactions for the different forms of BAR i.e. I, III and V were performed using Hirshfeld 206 
surfaces and represented as 2D fingerprint plots (ESI Figure S10).51 Significant differences were 207 
observed for the different forms. Notably, the higher contribution of the O⋯H interactions in form 208 
III (45%) compared to Form I and V (40.8% and 40.1%, respectively). Thus, it speculated that the 209 
polar end groups of the mimetic gelators may be able to interact with the nuclei of Form III more 210 
favorably and promote the growth due to a local supersaturation of this form over Form I or V.52 211 
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However, crystal growth mechanisms and the link between nuclei ordering and the final crystal 212 
structure are not well understood, and is beyond the scope of this work. 213 
 214 
 215 




Figure 3 Photos of BAR crystals produced from (a) solution crystallizations and (b) G1 gel phase 219 
crystallizations in (i) 1-butanol, (ii) ethanol, and (iii) nitromethane and (iv) cyclohexanone, 220 




  224 
Figure 4 PXRD patterns of BAR only polymorph III obtained inside the gel G1 in 1-butanol and 225 
the mixture of polymorphs obtained from solution crystallization from 1-butanol 226 
 227 
Thalidomide Crystallization 228 
(±)Thalidomide has very low solubility in most organic solvents and is practically insoluble in 229 
alcohols. So, the crystallization of this drug was restricted to nitromethane, 1,4-dioxane, 230 
nitrobenzene and cyclohexanone. To our knowledge concomitant polymorphism of THL has not 231 
previously been documented in the literature. Packing energy calculations were undertaken using 232 
Mercury 4.2.048 for the crystal structures (THALID11-12) deposited in the Cambridge Structural 233 
Database and demonstrated comparable packing energies for polymorphs α (‒150.6 kJ mol–1) and 234 
β (‒156.9 kJ mol–1). Interestingly, the two polymorphs crystallize concomitantly upon solution 235 
crystallization from nitromethane at concentration 20 mg/mL (Figure 5a). From the solution 236 
crystallization in nitromethane, large plate and small needle-shaped crystals were observed. The 237 
plate and needle-shaped crystals were characterized by FT-IR spectroscopy, PXRD, and unit cell 238 
parameter determination and confirmed as the α and β forms, respectively.35 The polymorphs can 239 
be easily distinguished by comparison of their FT-IR spectra in which the α polymorph exhibits  240 
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N-H stretching modes at 3193 and 3098 cm–1 while the β polymorph exhibits peaks at 3278 and 241 
3111 cm–1 as shown in Figure 6. Crystallization of THL in nitromethane G1 gels prevents this 242 
concomitant crystallization, such that only kinetic form α is formed (Figure 5b). To confirm the 243 
phase purity of the crystals obtained inside the gel the PXRD pattern was compared with that 244 
simulated from the single-crystal structure and they were found to be in an exact match (see ESI 245 
Figure S9). 246 
 247 
Figure 5 (a) Concomitant crystals plate (α) and needle (β) of THL obtained from solvent 248 
evaporation in nitromethane and (b) crystals of only α grown inside the G1 gel in nitromethane. 249 
 250 
  251 
Figure 6 FT-IR spectra comparisons of THL polymorphs α grown inside the gel (red) and 252 


































The FT-IR spectrum of the β polymorph of THL was obtained by manually separating the crystals 254 
(blue).  255 
 256 
Under comparable conditions no substantial changes in polymorphic outcome were observed 257 
between gel phase (G1) and solution phase crystallization by slow cooling in nitrobenzene, 1,4-258 
dioxane and cyclohexanone. However, the gel phase method resulted in a habit change with 259 
comparatively larger crystals being formed in the gels compared to solution crystallization in 1,4-260 
dioxane (Table 3).  261 
 262 
Table 3 Comparison of crystallization outcome from solution and Gel crystallization of THL 263 
Solvent Crystal forms in 
pure solvent 
Crystal forms 
from gel G1 
Crystal forms 
from gel G2 
Crystal forms 
from G3 gel  
Nitromethane α and β α No gel Gel not stable 
1,4-dioxane α α*  No gel No gel 
Cyclohexanone No crystals α* No gel No gel 
Nitrobenzene No crystals α†  α†  No crystals 
*large needles, †very small crystals 264 
Conclusions 265 
Three new bis(urea) based drug mimetic molecular organogelators were synthesized by the 266 
reaction of (±)aminoglutethimide with different diisocyanates. Rheological analysis and SEM 267 
images confirm that all three form supramolecular gels with the ethyl-substituted diphenylmethane 268 
gelator G1 being by far the most versatile, consistent with previous.4,17 The gelators were used as 269 
a crystallization media for crystallization of imide containing drugs barbital and (±)-thalidomide. 270 
While solution crystallization of BAR in many solvents gave rise to concomitant mixtures, gel 271 
phase crystallization using these novel gelators exhibited high selectivity towards the kinetic form 272 
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III polymorph of barbital. Similarly, in the case of THL, gels of G1 selectively crystallize the 273 
kinetic α form while concomitant mixtures of forms α and β were obtained using solution 274 
crystallization methods. It is speculated that the local order of the gel fibers may provide a 275 
preferred nucleation site for certain forms and sufficiently favor their crystallization to avoid 276 
concomitant crystallization. The use of non-mimetic gelators did not prevent concomitant 277 
crystallizations. This indicates that the viscous gel media is not primarily responsible for favoring 278 
the kinetic forms. Thus, the use of drug-mimetic gelators is necessary to prevent the concomitant 279 
crystallization of BAR and THL.  This work demonstrates a promising route to preventing 280 
concomitant crystallization in other systems.  281 
 282 
Experimental  283 
Materials and Methods 284 
All the chemicals used were brought from standard commercial sources and were used as such 285 
without further purification. (±)-aminoglutethimide was purchased from TCI. The isocyanates 286 
were purchased from Sigma Aldrich. All solvents of HPLC grade, triethylamine, and chloroform 287 
used in the experiments were purchased from Merck.  288 
FTIR spectra of the gelators and the obtained polymorphic form of the drug BAR and THL were 289 
recorded in the frequency range of 600–4000 cm–1 in a Perkin Elmer Spectrum 100 ATR 290 
instrument. Powder diffraction patterns were recorded on a PANalytical Empyrean diffractometer 291 
using Cu Kα radiation (λ = 1.54Å), tube voltage of 40kV and 40mA current. Intensities were 292 
measured from 5° to 50° 2θ with 0.04 rad. Soller silts and an incident beam divergent slit of 1/8°, 293 
antiscatter slit of 1/4° and diffracted beam anti-scatter slit of 7.5mm (PIXcel). All NMR spectra 294 
were recorded using a Varian Mercury 400 (1H: 400 MHz; 13C: 100 MHz) spectrometer at room 295 
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temperature using deuterated solvent DMSO-d6. Mass spectra of the compounds were collected 296 
using a Thermo-Finnigan LTQ FT mass spectrophotometer. Samples were dissolved in methanol 297 
and mass spectra were collected in positive electron spray (ES) mode in the case of G2 and G3, 298 
whereas matrix-assisted laser desorption/ionization (MALDI) was used for G1. Elemental analysis 299 
is performed by using an Exeter Analytical Inc. CE-400 elemental analyzer. Typical sample size 300 
5-7 mg was used to calculate the C, H and N percentage of the prepared compounds. Rheological 301 
experiments were performed using advanced rheometer AR 2000 from TA Instruments. The 302 
rheometer was equipped with a chiller (Julabo C). Stainless steel 20 mm plain plate geometry was 303 
used to perform the experiments. Samples of the gels were prepared in different concentration 304 
using different solvents in 7 mL glass vials. The obtained gels were transferred on to the center of 305 
the plate of the rheometer using a spatula. The strain sweep measurements were performed to 306 
estimate the strain at a constant stress of 10 Pa. Next, frequency sweep measurements and time 307 
sweep measurements were performed in the range 0.1 to 4000 Pa. SEM images were obtained on 308 
a Hitachi S-5200 field emission scanning microscope. The samples were prepared by applying 309 
directly to silicon wafer chips (Agar Scientific) using a stick. Then the samples were kept in 310 
vacuum for slow evaporation of solvents. All three samples were coated with 2 nm of Pt and were 311 
imaged at 3 KeV and 0.34 nA.  312 
 313 
Characterization of gelators 314 
See ESI for details of gelator synthesis. 315 
Gelator G1: Yield = 0.378 g, 0.46 mmol, 85%, MP > 300 ºC. FT-IR: 3320 (N–H), 1692 (C=O), 316 
1650 (N–Hbend) cm
−1; 1H-NMR (DMSO-d6, 400MHz) δ:  0.75 (t, J = 7.6 Hz, 6H, -CH3) 1.10 (t, J 317 
= 8.0 Hz, 12H, -CH3), 1.75-1.87 (m, 4H, -CH2), 2.08–2.19 (m, 4H, -CH2), 2.31–2.46 (m, 4H, -318 
 20 
CH2) 2.51–2.55 (m, 8H, -CH2), 3.85 (s, 2H, -CH2), 6.99 (s, 4H, H-Ph), 7.16 (d, J = 8.0 Hz, 4H, H-319 
Ph), 7.43 (d, J = 8.0 Hz, 4H, H-Ph), 7.56 (s, 2H, NH), 8.82 (s, 2H, NH), 10.83 (s, 2H, NH).13C{1H}-320 
NMR (DMSO-d6, 100 MHz): δ 176.3, 173.2, 154.3, 142.3, 140.1, 139.7, 132.6, 132.2, 127.0, 321 
126.7, 118.2, 50.0, 32.6, 29.5, 26.4, 24.9, 15.1 and 9.3 ppm. MALDI-TOF MS calc. for M+H 322 
828.02, experimental 828.00. Elemental analysis: Calc. (%) C, 71.20; H, 7.07; N, 10.03; found. 323 
(%) C, 71.18; H, 7.11; and N, 10.03. 324 
Gelator G2: Yield= 0.346 g, 0.48 mmol, 90%, MP > 300 ºC. FTIR: 3337 (N–H), 1691 (C=O), 325 
1650 (N–Hbending) cm
−1; 1H-NMR (DMSO-d6, 400MHz) δ: 0.75 (t, J = 7.4 Hz, 6H, -CH3), 1.77–326 
1.84 (m, 4H, -CH2), 2.09-2.17 (m, 4H, -CH2), 2.31–2.47 (m, 4H, -CH2),  3.81 (s, 2H, -CH2), 7.11 327 
(d, J = 8.0 Hz, 4H, H-Ph), 7.18 (d, J = 8.0 Hz, 4H, H-Ph), 7.34 (d, J = 8.0 Hz, 4H, H-Ph), 7.43 (d, 328 
J = 8.0 Hz, 4H, H-Ph), 8.57 (s, 2H, NH), 8.65 (s, 2H, NH), 10.83 (s, 2H, NH). 13C{1H}-NMR: 329 
(DMSO-d6, 100 MHz): δ176.3, 173.2, 152.9, 139.1, 137.9, 135.5, 133.1, 129.3, 127.1, 118.84, 330 
118.8, 50.1, 32.6, 29.6, 26.4, and 9.3. MS calculated for M+2H is 357.16, experimental 357.39. 331 
Elemental analysis: Calc. (%) C, 68.89; H, 5.92; N, 11.76, found (%): C, 68.29; H, 5.81; and N, 332 
11.65. 333 
 334 
Gelator G3: Yield= 0.329 g, 0.47 mmol, 87%, MP > 300 ºC.  FT-IR: 3341 (N–H), 1695 (C=O), 335 
1641 (N–Hbending) cm
−1. 1H-NMR (DMSO-d6, 400MHz) δ: 0.74 (t, J = 8.0 Hz, 6H, -CH3), 1.59 (s, 336 
12H, -CH3), 1.77–1.82 (m, 4H, -CH2), 2.06–2.16 (m, 4H, -CH2), 2.28–2.43 (m, 4H, -CH2), 6.54 337 
(s, 2H, NH), 7.10 (d, J = 8 Hz, 4H, H-Ph), 7.23 (s, 4H, H-Ph), 7.31 (d, J = 8.0 Hz, 4H, H-Ph), 8.45 338 
(s, 2H, NH), 10.81 (s, 2H, NH).13C{1H}-NMR: (DMSO-d6, 100 MHz): δ 176.3, 173.2, 154.8, 339 
148.3, 139.9, 132.2, 128.0, 126.9, 122.9, 121.7, 118.1, 55.0, 50.0, 46.1, 32.6, 30.2, 29.5, 26.4, 12.1, 340 
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and 9.3. MS calculated for M+H is 709.36, experimental 709.55. Elemental analysis: Calc. (%): 341 
C, 67.78; H, 6.83; N, 11.86; found (%): C, 67.39; H, 6.62; and N, 11.56 342 
 343 
Gel Screening 344 
Gel screening was carried out at a concentration of 2 % (w/v). Samples were dissolved in 0.5 345 
mL of the relevant solvent through gentle heating close to the boiling temperature followed by 346 
sonication for 1 min. Gels formation was generally observed within a few minutes but in some 347 
case, it requires several hours.  348 
 349 
Solution and Gel Phase Recrystallization 350 
Solution crystallizations were performed by the heating of a saturated solution of either BAR or 351 
THL until completely dissolved. The solutions were left to cool slowly in a heating block. These 352 
were carried out in parallel with gel-phase crystallizations under the same conditions, but in which 353 
the heated solution was used to dissolve the gelator. Then the solutions were also left to cool slowly 354 
in the heating blocks. Typically gels formed in a few minutes and crystals formed over a matter of 355 
hours or days. 356 
 357 
Crystal Form Characterisation  358 
Crystals obtained from the solution and gel phase crystallisation experiments were characterized 359 
using single crystal x-ray diffraction, XRPD, DSC and microscopic technique.  360 
 361 
Supporting Information 362 
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Further gelator characterization as well as FT-IR, rheological and XPRD data and Hirshfeld 363 
surface analysis available in the electronic supporting information.  364 
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